The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 1068-1074

  Saito, Teruyoshi ^a   Dai, Tamura ^a   Asano, Ryuji ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

4 methylumbelliferone; Apoptosis; Canine mammary tumor; Chemokinesis; Chemotaxis; Hyaluronan; Hyaluronan synthase

Indexed keywords

HYALURONIC ACID; HYMECROMONE; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; PROTEIN BAX; UVOMORULIN; VIMENTIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOKINESIS; CHEMOTAXIS; CONTROLLED STUDY; DOG; DOWN REGULATION; FLOW CYTOMETRY; MESENCHYME CELL; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84872699887     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1124     Document Type: Article

References (36)

1. Weismann B, Rapport MM, Linker A and Meyer K: Isolation of the aldobionic acid of umbilical cord hyaluronic acid. J Biol Chem 205: 205-221, 1953.
2. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539, 2004.
3. Knudson CB and Knudson W: Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 7: 1233-1241, 1993.
4. Auvinen P, Tammi R, Parkkinen J, et al: Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156: 529-536, 2000.
5. Itano N and Kimata K: Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol 18: 268-274, 2008.
6. Udabage L, Brownlee GR, Waltham M, et al: Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 65: 6139-6150, 2005.
7. Udabage L, Brownlee GR, Nilsson SK and Brown TJ: The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310: 205-217, 2005.
8. Li Y, Li L, Brown TJ and Heldin P: Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 120: 2557-2567, 2007.
9. Nakamura T, Funahashi M, Takagaki K, Munakata H, Tanaka K, Saito Y and Endo M: Effect of 4-methylumbelliferone on cell-free synthesis of hyaluronic acid. Biochem Mol Biol Int 43: 263-268, 1997.
10. Kakizaki I, Kojima K, Takagaki K, et al: A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-Methylumbelliferone. J Biol Chem 279: 33281-33289, 2004.
11. Kultti A, Pasonen-Seppänen S, Jauhiainen M, et al: 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315: 1914-1923, 2009.
12. Lokeshwar VB, Lopez LE, Munoz D, et al: Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res 70: 2613-2623, 2010.
13. Yoshihara S, Kon A, Kudo D, et al: A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 579: 2722-2726, 2005.
14. Arai E, Nishida Y, Wasa J, et al: Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Brit J Cancer 105: 1839-1849, 2011.
15. Urakawa H, Nishida Y, Wasa J, et al: Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 130: 454-466, 2012.
16. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
17. Liotta LA, Mandler R, Murano G, et al: Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83: 3302-3306, 1986.
18. Shintani Y, Maeda M, Chaika N, Johnson KR and WheelockMJ: Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol 38: 95-104, 2008.
19. Zoltan-Jones A, Huang L, Ghatak S and Toole BP: Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 278: 45801-45810, 2003.
20. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metast Rev 28: 15-33, 2009.
21. Benjamin SA, Lee AC and Saunders WJ: Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 36: 423-436, 1999.
22. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gärtner F and Gruber AD: Molecular carcinogenesis of canine mammary tumors: News from an old disease. Vet Pathol 48: 98-116, 2011.
23. Uva P, Aurisicchio L, Watters J, et al: Comparative expression pathways analysis of human and canine mammary tumors. BMC Genomics 10: 135, 2009.
24. Meuten DJ: Tumors in Domestic Animals. Meuten DJ (ed.) Iowa State Press, pp575-606, 2002.
25. Saito T, Kawana H, Azuma K, Toyoda A, Kitagawa M and Harigaya K: Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane. Int J Oncol 39: 1311-1320, 2011.
26. Toyoda A, Yokota A, Saito T, et al: Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers. Int J Oncol 38: 89-96, 2011.
27. Christiansen JJ and Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326, 2006.
28. Xia W, Spector S, Hardly L, Zhao S, Saluk A, Alemane L and Spector NL: Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. Proc Natl Acad Sci USA 97: 7494-7499, 2000.
29. Hu M, Pollock RE and Nicolson GL: Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragments of human fibronectin. Cancer Res 57: 3577-3584, 1997.
30. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, SaarikoskiSV and Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60: 150-155, 2000.
31. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U and Kosma VM: High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37: 849-856, 2001.
32. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, DuncanRC and Lokeshwar VB: Evaluation of prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 63: 2638-2644, 2003.
33. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L and HungMC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272: 27913-27918, 1997.
34. Ouhit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF and RajMH: In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol 171: 2033-2039, 2007.
35. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
36. Paltian V, Alldinger S, Baumgärtner W and Wohlsein P: Expression of CD44 in canine mammary tumours. J Comp Path 141: 237-247, 2009.